Bis-amide Compounds Inhibiting SARS-CoV-2 via Preliminary Action

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments lack effective solutions for severe acute respiratory syndrome caused by SARS-CoV-2, with no established drugs available to address the urgent medical need.

Innovation Solution

Development of specific compounds, such as those represented by formulas (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), and (Ig), or their pharmaceutically acceptable salts, which inhibit SARS-CoV-2 and are administered as part of a pharmaceutical composition to treat severe acute respiratory syndrome.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If no specific antiviral treatment is available for SARS-CoV-2, then the urgency of the medical need increases, but the effectiveness of treatment options remains zero

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidavailability of treatment options

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies preliminary action by developing and testing compounds (such as those in formulas I, Ia, Ib, Ic, Id, If, and Ig) before the full emergence of COVID-19 pandemic impacts. The research was conducted in advance to have therapeutic options ready when the virus outbreak occurred, allowing rapid deployment of pre-developed antiviral compounds rather than starting from scratch during the crisis.

Inventive Principle:

Principle #10Preliminary action

2Adaptability or versatility

If general antiviral approaches are used without specific SARS-CoV-2 targeting, then broad applicability is maintained, but efficacy against SARS-CoV-2 is insufficient

Engineering Contradiction:

Improvebroad applicabilityVSAvoidefficacy against SARS-CoV-2

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent applies local quality by designing compounds with specific structural features (formulas I, Ia, Ib, Ic, Id, If, and Ig) that are optimized for SARS-CoV-2 inhibition. The molecular structures contain specific functional groups and configurations that target SARS-CoV-2 replication mechanisms, while maintaining enough structural flexibility to potentially adapt to related coronaviruses, thus achieving both specificity and some broad applicability.

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS20230159516A1Compounds for the treatment of sars

Publication Date: 2023.05.25 PURDUE RES FOUND

AI summary

Bis-amide inhibitors of SARS-CoV-2 (COVID), pharmaceutical compositions comprising same; and methods of treating a severe acute respiratory syndrome.